Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Lapam Capital

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 23
Average round size
The average size of a deal this fund participated in
Portfolio companies 22
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Medical
  • Biopharma

The main office of represented VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.

Among the most popular fund investment industries, there are Clinical Trials, Medical. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Connect Biopharmaceuticals, Stemirna Therapeutics, Asieris Pharmaceuticals. The fund has exact preference in some founders of portfolio startups.

The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Lapam Capital, startups are often financed by TF Capital, Qiming Venture Partners, XinYue Equity. The meaningful sponsors for the fund in investment in the same round are ZGC Group, Qiming Venture Partners, Zhongguancun VC Development Center. In the next rounds fund is usually obtained by Qiming Venture Partners, Northern Light Venture Capital, Cowin Capital.

The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The fund is generally included in 2-6 deals every year. The high activity for fund was in 2017.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Lapam Capital:
Typical Co-investors
Lapam Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Lapam Capital:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Ascend Venture Capital Missouri, Saint Louis, United States
Bonaventure Capital Alabama, Birmingham, United States
BrainLAB Bayern, Germany, Munich
CD Capital England, London, United Kingdom
CityBlock Capital New York, New York, United States
CR Capital Management Beijing, Beijing, China
Denshi-koen Japan, Tokyo
Diaspora Angel Network -
Gaea Technology China, Guangdong, Shenzhen
Grosvenor Capital Management Chicago, Illinois, United States
Investment Partners Metuchen, New Jersey, United States
Keller Enterprises Charlottesville, United States, Virginia
MSouth Equity Partners Atlanta, Georgia, United States
Oryzn Capital Israel, Tel Aviv, Tel Aviv
Pobox -
Pod Investment Stockholm, Stockholm County, Sweden
Taifu Capital China, Shanghai
WILD Group Management Switzerland, Zug, Zug
Yongjin Group China, Shanghai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$20M15 May 2022 Birmingham, Alabama, United States

Pleryon Therapeutics

$15M01 Apr 2022 Shenzhen, Guangdong, China

Chance Pharmaceuticals

Health Care
$30M11 Oct 2021 Hangzhou, Zhejiang, China

Leads Biolabs

Health Care
$100M08 Oct 2021 Nanjing, Jiangsu, China

Ranok Therapeutics

$40M19 Aug 2021 Hangzhou, Zhejiang, China

Kangpu Bio-Pharma

Clinical Trials
Health Care
$38M10 May 2021 Shanghai, China

Yingbairui Shengwu

13 Mar 2021 -

Binhui Biotech

$92M10 Feb 2021 Wuhan, Hubei, China

$72M20 Aug 2020 Siming, Fujian
Ranok Therapeutics Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline

– Ranok Therapeutics (Hangzhou) Co. Ltd. secured a $40m Series B funding round denominated in both U.S. dollars and Chinese yuan.
– The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors.
– To date, Ranok has raised the equivalent of over $50m in funding.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Lapam Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: